|
1 kits (10 Vials)
| Yawan: | |
|---|---|
▎ Tsarin Cagrilintide
Source: PubChem |
Jeri: Pyr-KCNTACATQRLAEFLRHSSNNFGPILPPTNVGSNTP Saukewa: 1415456-99-3 Formula: C 174H 269N 45O 52S2 MW 4409 g/mol |
▎ Binciken Cagrilintide
Menene asalin binciken Cagrilintide?
Cagrilintide shine amylin dual da calcitonin agonist mai karɓa (DACRA) wanda aka haɓaka bisa tsarin amylin. Amylin yana ɓoye ta sel beta na pancreatic kuma yana aiki tare da insulin don aiwatar da ayyuka daban-daban na jiki. Yana iya haifar da jin daɗin jin daɗi da rage cin abinci, galibi ta hanyar kunna masu karɓa a cikin yankin postrema a gindin ventricle na huɗu. Ana watsa siginar jijiyoyi zuwa kwakwalwar gaba ta tsakiya ta tsakiya kuma ana iya yada shi zuwa yankin hypothalamic na gefe da sauran kungiyoyin nukiliya ta hanyar tsakiya na parabrachial na gefe, don haka mai ban sha'awa cibiyar satiety da hana ci abinci [1] . Amylin kuma na iya daidaita glucose homeostasis ta hanyar hana fitar da insulin da glucagon don kula da daidaiton matakan glucose na jini [2] . Hanyoyin sa sun haɗa da tasiri kai tsaye akan ƙwayoyin sel na pancreatic islet α da tsarin kai tsaye na ɓoyewar glucagon ta hanyar siginar jijiya a cikin hypothalamus. A cikin marasa lafiya da ciwon sukari, lalata ƙwayoyin β suna haifar da raguwar ƙwayar amylin. Amylin yana shiga cikin tsarin tsarin glucose homeostasis ta hanyar hana zubar da ciki da kuma samar da glucose na hanta bayan prandial, yana rage jujjuyawar glucose na jini bayan faɗuwa. Hakanan yana iya jinkirta zubar da ciki, hana peristalsis na gastrointestinal, tsawaita lokacin zama na abinci, da hana hauhawar glucose na jini. Koyaya, ɗan gajeren rabin rayuwar amylin na halitta yana iyakance aikace-aikacen asibiti. Ko da yake ana samun pramlintide a matsayin magani na adjuvant, yana buƙatar allura guda uku a rana, wanda ba shi da kyau kuma yana haifar da rashin bin doka [3] . Don magance wannan batu, an haɓaka Cagrilintide. Bincikensa da haɓakawa sun dogara ne akan zurfin fahimtar ayyukan ilimin lissafin jiki na amylin na halitta, yana nufin yin koyi da tsarin aikin sa yayin da yake inganta kwanciyar hankali da kuma tsawon lokaci na miyagun ƙwayoyi don saduwa da bukatun asibiti.
Menene Cagrilintide?
Cagrilintide sabon labari ne na amylin analog na dogon lokaci tare da babban yuwuwar, wanda ya riga ya nuna tasirin farko a cikin maganin kiba da ciwon sukari. An lipided kuma yana da halaye masu tsayi da tsayi [3] . Ana fitar da Amylin tare da insulin ta ƙwayoyin β na pancreatic kuma yana haifar da jin daɗin jin daɗi ta hanyar yin aiki akan yankunan gida da jin daɗi na kwakwalwa. A matsayin analog, Cagrilintide na iya yin kwaikwayon wannan tasirin, yana haifar da satiety don taimakawa sarrafa nauyin jiki. A lokaci guda, a matsayin mai dual amylin da calcitonin agonist agonist (DACRA), an samo shi daga kashin baya na amylin kuma yana da tsari na musamman a cikin tsarin rayuwa.
Samfurin Tsarin Cagrinlintide
Source:PubMed [3]
Menene aikace-aikacen da ke da alaƙa na Cagrilintide?
A cikin gwaje-gwaje na asibiti, Cagrilintide ya sami sakamako mai kyau a cikin haifar da asarar nauyi. Alal misali, a cikin multicenter, bazuwar, makafi biyu, mai sarrafa wuribo, da kuma gwadawa mai aiki na Phase 2 kashi-kashi gwajin gwaji, idan aka kwatanta da ƙungiyar placebo, matsakaicin kashi na asarar nauyi daga tushe a cikin kowane kashi na Cagrilintide (0.3 - 4.5 mg) (6.0% - 10.8%) (6.0% - 10.8%) ya fi wannan a cikin placebo (3.0%). Rashin nauyi a cikin ƙungiyar 4.5 MG kuma ya fi haka a cikin rukunin 3.0 MG na liraglutide (10.8% vs. 9.0%), yana nuna cewa zai iya zama zaɓi mai tasiri don sarrafa nauyi [4] . Cagrilintide yana da tsarin aiki na daban amma yana da alaƙa idan aka kwatanta da GLP-1 mai karɓar agonist semaglutide. Semaglutid yana rage cin abinci, yana ƙara haɓakar insulin, kuma yana jinkirta zubar da ciki ta hanyar aiki akan masu karɓar GLP-1 a cikin hypothalamus, yayin da Cagrilintide ya ƙara rage ci ta hanyar kunna mai karɓar amylin. Haɗin yin amfani da su biyu na iya haifar da tasiri mai mahimmanci, yana haɓaka tasirin asarar nauyi [5] . Idan aka yi la'akari da rikitaccen kiba, wannan haɗin gwiwar magani dabara ce mai ma'ana da inganci.
A cikin marasa lafiya da ke da nau'in ciwon sukari na 2, Cagrilintide shima ya nuna kyakkyawan ikon sarrafa glucose na jini. Nazarin asibiti ya nuna cewa yana da kyakkyawar kwanciyar hankali da tasiri a cikin maganin kiba da nau'in ciwon sukari na 2. Alal misali, a cikin gwaji na asibiti na marasa lafiya da nau'in ciwon sukari na 2, haɗuwa da amfani da Cagrilintide da GLP-1 agonist agonist semaglutide sun nuna kyakkyawar kulawar glucose na jini da kuma tasirin asarar nauyi [6] . Wani gwaji kuma ya nuna kyakkyawan haƙuri da aminci lokacin amfani da shi kadai ko a hade tare da semaglutide [6] , saboda kwanciyar hankali na miyagun ƙwayoyi yana da alaƙa da haƙuri da aminci.
Bugu da ƙari, Cagrilintide an yarda da shi sosai a cikin gwaji na asibiti. A cikin gwajin neman kashi na 2 na lokaci, ƙimar dakatarwar dindindin a cikin kowane rukunin jiyya sun kasance iri ɗaya, galibi saboda abubuwan da ba su da kyau. Duk da haka, mafi yawan abubuwan da suka fi dacewa su ne cututtuka na ciki da kuma halayen wurin allura, kuma yawancin su sun kasance masu sauƙi zuwa matsakaici. A cikin bazuwar, gwajin gwaji na Phase 1b, haɗin haɗin gwiwar Cagrilintide da 2.4 MG semaglutide kuma ya nuna kyakkyawan haƙuri da aminci [7] . Ana buƙatar gwaje-gwaje mafi girma da na dogon lokaci a nan gaba don kimanta inganci da amincin wannan haɗin gwiwar.
Cagrilintide yana kawo sabon bege don maganin kiba da nau'in ciwon sukari na 2. Yana ba da sabon zaɓin magani ga majinyata masu kiba, musamman waɗanda ba sa amsa da kyau ga ayyukan rayuwa kuma ba su dace da tiyatar bariatric ba. Tsarin aikinsa na musamman yana ba da sabbin dabaru da hanyoyin magance kiba, kuma yana iya samun fa'idodi fiye da magungunan asarar nauyi na gargajiya (D'Ascanio AM, 2024). Halin nasara na haɗuwa da amfani da Cagrilintide da semaglutide (CagriSema) ya nuna cewa haɗin gwiwar da aka yi niyya da yawa shine ingantaccen dabarun inganta amsawar jiyya don kiba [6] . Wannan samfurin yana ba da sabon salo don sarrafa kiba kuma yana kawo ingantaccen haɓakar rayuwa ga marasa lafiya da ke da nau'in ciwon sukari na 2.
A ƙarshe, a matsayin sabon labari na amylin analog na dogon lokaci, Cagrilintide yana da babban yuwuwar asarar nauyi da sarrafa glucose na jini. Yana kunna hanyar siginar satiety ta hanyar kwaikwayon aikin amylin kuma yana daidaita metabolism azaman agonist mai karɓa biyu. Gwaje-gwaje na asibiti sun nuna cewa Cagrilintide, ko dai shi kadai ko a hade tare da semaglutide, na iya rage nauyin jiki sosai kuma yana da kyau. Bugu da kari, ya kuma nuna kyakkyawan ikon sarrafa glucose na jini a cikin marasa lafiya da ke da nau'in ciwon sukari na 2, yana ba da sabon zaɓin jiyya don magance kiba da ciwon sukari, cike gibin da ke tattare da tsarin jiyya da ake da su, musamman ga marasa lafiya waɗanda ba su amsa da kyau ga ayyukan rayuwa kuma ba su dace da tiyata ba. Dabarun jiyya na manufa da yawa yana ba da sababbin ra'ayoyi don gudanar da cututtuka na rayuwa.
Game da Marubuci
Abubuwan da aka ambata a sama duk bincike ne, gyara su kuma Cocer Peptides ne suka haɗa su.
Mawallafin Jaridar Kimiyya
Dr. DCW Lau farfesa ne a Makarantar Magunguna ta Cumming, Jami'ar Calgary, Kanada. Abubuwan bincikensa sun haɗa da ilimin endocrinology da metabolism, magani na gabaɗaya da na ciki, tsarin zuciya da jijiyoyin jini da cututtukan zuciya, lafiyar jama'a, lafiyar muhalli da aikin sana'a, gami da oncology. Ya kuma rike mukamai tare da Sabis na Lafiya na Alberta (AHS) da Kiba Kanada kuma yana aiki a Cibiyar Binciken Ciwon sukari na Julia McFarlane. Dokta Lau yana da kwarewa sosai a fannin binciken ciwon sukari da kuma kiba, tare da buga aikinsa a cikin mujallu na ilimi kamar Canadian Journal of Diabetes. An jera Dr. DCW a cikin ambaton ambaton [4].
